| Code | CSB-RA003996MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Izastobart, targeting C5AR1 (Complement Component 5a Receptor 1), also known as CD88. C5AR1 is a G protein-coupled receptor that mediates the pro-inflammatory effects of complement component C5a, playing a critical role in innate immune responses and inflammatory cascades. Upon C5a binding, C5AR1 triggers neutrophil chemotaxis, mast cell degranulation, and the release of inflammatory mediators. Dysregulated C5AR1 signaling has been implicated in various pathological conditions including sepsis, acute respiratory distress syndrome, rheumatoid arthritis, inflammatory bowel disease, and certain neurodegenerative disorders.
Izastobart is a therapeutic antibody designed to block C5AR1 activation and mitigate excessive complement-mediated inflammation. This biosimilar provides researchers with a valuable tool for investigating C5AR1-mediated pathways, studying complement system biology, and exploring potential therapeutic interventions in inflammatory and autoimmune diseases. It serves as an important reagent for preclinical studies examining the role of C5a-C5AR1 axis in disease pathogenesis and for validating complement-targeted therapeutic strategies.
There are currently no reviews for this product.